Home Blog Page 896

Allegheny Health Network Launches Mask Sterilization and Re-use Program to Support COVID-19 Pandemic Response Efforts

Allegheny Health Network announced that a novel process that sterilizes N95 respiratory masks after their initial use can extend the lifespan of these critical devices, allowing them to be worn multiple times by caregivers and helping to alleviate the stress that mask supply shortages have had on health care providers across the country.

Over the weekend, Allegheny Health Network began sterilizing masks for re-use at each of its nine surgical hospitals. The new process, recently approved by the Centers for Disease Control and Prevention, enables AHN to sterilize thousands of masks per day, and instantly increases AHN’s supply of available N95 respirators for caregivers.

Allegheny Health Network is the first health care organization in the region to implement an N95 recycling program as part of its novel coronavirus (COVID-19) pandemic response efforts.

“With masks and other kinds of personal protective equipment in short supply, AHN and Highmark Health have been working tirelessly to ensure that our patients are safe and that our clinical employees always have the protective equipment they need,” said Sricharan Chalikonda, MD, Chief Medical Operations Officer, Allegheny Health Network.”Sometimes, that means finding new sources for those products. In this case, we have developed an outside-of-the-box approach to make more efficient use of the products we already have on hand.”

Normally, disposable masks such as N-95s are not permitted to be reused. But because of an ongoing supply shortage driven by the worldwide COVID-19 pandemic, the FDA is temporarily authorizing health care providers to sterilize masks for re-use with in-house sterilization equipment that is typically used to sterilize and decontaminate surgical tools and other health care instrumentation.

But with Allegheny Health Networkand most other health systems postponing elective surgeries, those machines are now available for other uses. AHN’s perioperative surgical team and its nursing staff spent the last week designing and implementing a system that would allow the masks to be collected, brought to the hospitals’ central sterilization departments, and redistributed.

“Re-using the N95 respirators produces a number of benefits,” said Hope Waltenbaugh, MSN, RN, vice president of surgical services.

“First and foremost, it prolongs the life of our masks and helps to ensure that our front-line caregivers are always protected. It also cuts down on hospital waste, and potentially opens the door to sterilizing and re-processing other types of masks, or other forms of personal protective equipment.”

N95 respirator masks are different than surgical “ear loop” masks; they are tight-fitting devices that reduce the wearer’s exposure to airborne particles, including large droplets and aerosolized particles. They are used in environments where there is a high risk of exposure to airborne agents and are critical resources for health care workers who are treating or collecting samples from COVID-19 patients.

Once used masks have been delivered to the hospital’s central sterilization department, they’ll be inspected for wear and tear, elastic damage, stains, makeup, or any other imperfection. Damaged masks will be discarded.

Masks that are selected for reuse will then be sealed into sterilizing peel-pack envelopes and loaded into the sterilization machine, which can accommodate up to 40 masks per load. Before the masks are sterilized, they will be tagged with a tape strip, to mark it as a recycled mask.

The N95 masks can be recycled twice before being discarded. Allegheny Health Networkhopes that it will eventually be able to recycle more than 80 percent of its N95 masks.

Each load takes about 45 minutes to complete, and each machine can sterilize about 15 loads per day, using hydrogen peroxide vapor. Previous studies conducted by Duke University and others have demonstrated that N95 respirators still meet performance requirements even after 50 decontaminations with this process.

Allegheny General Hospital and West Penn Hospital will have two mask-sterilizing machines on site; the rest of AHN’s hospitals will have one. At full capacity, machines across the network could collectively recycle more than 6,000 masks per day, with the help of AHN’s central sterilization technicians.

“In our fight against COVID-19, nurses and doctors are getting much of the credit, and deservedly so,” Waltenbaugh said. “But central sterilization technicians and environmental services employees work extremely hard to keep our facilities, equipment, and instruments clean, and they can be exposed to the same pathogens as our clinical caregivers. They are health care’s unsung heroes.”

Allegheny Health Networkcollaborated with Pittsburgh-based MSA Safety to test the performance of the respirators following the sterilization process. Last month, MSA helped secure a shipment of N95 masks for the Pittsburgh region that were donated to various health care providers and first responders in the community.

Nova Biomedical Adds PT/INR Test to Allegro® Analyzer

Nova Biomedical has announced the addition of PT/INR testing for its Allegro capillary blood analyzer for point-of-care (POC) testing in primary care settings. Now with the ability to test for clotting disorders and monitor the effectiveness of blood-thinning medications, the Allegro, and its StatStrip-A companion meter provide 18 clinically important tests to help physicians make therapeutic decisions and adjustments at the point-of-care. The Allegro analyzer and this new PT/INR test are available now for purchase in CE regulated countries.

This upgrade allows Allegro to monitor patient coagulation therapy in addition to testing for glycemic control, kidney function, anemia, gout, and cardiac risk with a full lipids panel. PT/INR is just one of 18 tests for the Allegro platform, including HbA1c, Cholesterol, Triglycerides, Glucose, Creatinine, UACR, Hemoglobin, Hematocrit, and Uric Acid.

Allegro is a compact, fast, and simple POC analyzer that features a clinically important menu of twelve measured and individually selectable tests, plus six calculated tests. All Allegro tests use easy capillary fingerstick sampling, eliminating the need for venipunctures or a trained phlebotomist, and easy-to-use disposable test cartridges or strips. Allegro’s quick six to nine-minute cartridge test times and the ability to measure two cartridges simultaneously provide rapid results immediately to the physician.

Allegro is ideal for primary care settings with tests that are easily performed by non-technical personnel and feature disposable, ready-to-use cartridges and test strips. All results are ready during the patient visit, simplifying clinic workflow and producing cost savings for providers while offering clinical benefits for patients.

Allegro is the only analyzer that can measure HbAlc, lipids, glucose, and creatinine from a capillary sample. Its innovative design comprises dual measurement bays, which offers the unique ability to measure two cartridges simultaneously, doubling throughput and improving efficiency.

Allegro’s companion meters wirelessly transmit results to the analyzer, where they combine with all cartridge test results for one patient report. All results can be transmitted to electronic medical records for providers to review with patients during the visit. Having immediate results during the patient visit reduces clinic follow-up calls, letters, and patient re-visits, and improves patient satisfaction, compliance with care plans, and outcomes.

 

Remote Electrical Neuromodulation Reported As Viable Alternative to Drugs for Acute Migraine

Remote Electrical Neuromodulation:

Theranica Bioelectronics (Theranica), is a bio-medical technology company developing advanced electroceuticals for migraine and other pain conditions.  Today the company announced that Frontiers In Neurology Journal published an article demonstrating that incorporating Remote Electrical Neuromodulation (REN) treatment into usual care of migraine has the potential to reduce reliance on acute pharmacological medications.

“This study signals a potentially significant shift in how we approach the acute treatment of migraine,” said lead author Michael Marmura, MD, Headache Specialist at the Thomas Jefferson University Hospital in Philadelphia. “Adding REN as an alternative to traditional migraine treatments opens the door to new long-term treatment strategies. What is most promising is the fact that so many patients in the study chose REN without being specifically prompted, and experienced treatment outcomes similar or slightly better than their usual care.”

In a cohort of 117 patients who were given the option of using REN in addition to or instead of their usual care treatments, such as triptans or over-the-counter (OTC) medications, 89.7% used REN exclusively, without medications. When REN was not available, only 15.4% chose to avoid medications in all their reported migraine attacks. The patients who used REN exclusively reported similar treatment outcomes to their usual (pharmacological) care. The article concludes that “Incorporating REN into usual care may have a positive impact on migraine management by reducing the reliance on acute medications.”

“When patients experience debilitating migraine symptoms, they are looking for effective relief,” said Dr. Morris Levin, chief of the headache medicine division and director of the Headache Center at UCSF Medical Center in San Francisco, who served as the chairman of the independent Data and Safety Monitoring Committee of the study. “Traditionally we’ve had only a limited number of useful acute migraine treatments, many of which have side effects. REN is a welcome option, due to its apparent safety and almost nonexistent adverse effects.  In addition, the risk of medication overuse, often a limiting factor with acute medications, should not be an issue when using a drug free therapy such as REN.”

The device used in the study was Theranica’s FDA-authorized prescribed therapeutic wearable, Nerivio. The device deploys REN to activate the body’s native Conditioned Pain Modulation (CPM) mechanism to treat pain and accompanying migraine symptoms. Nerivio, which was recently named one of TIME’s best inventions of 2019, is available in the US with a valid prescription. It is also accessible via online telemedicine portals Cove or UpScript, which provide physician consultations and home delivery.


Other device industry news items can be found here.

Sharp Fluidics® Acquires neoClose® Laparoscopic and Robotic Port Closure Technology

April 7, 2020

Sharp Fluidics®, LLC, is a private medical device company whose innovative Operative Armour® System leads the way in open surgery closure efficiency and safety, announced the acquisition of neoClose®, a laparoscopic and robotic port site closure technology from neoSurgical, LTD.

“This is a significant step to enhance Sharp Fluidics’ product portfolio,” said Doug Rimer, President, Sharp Fluidics, LLC. “We strive to introduce innovative thinking to surgical closure, and neoClose is highly complementary to our Operative Armour System. With Operative Armour, clinicians can self-dispense and self-secure their own suture needles in open surgery closures without scrub tech assistance, dramatically improving workflow efficiency while minimizing exposure to contaminated suture needles. neoClose enables us to now offer an extremely elegant and user-friendly, needle-less approach to perform safer, more efficient closure of minimally invasive surgeries.”

neoClose® brings a simple, intuitive, and reliable solution to assist the surgeon in closing port site defects, up to 3cm, following laparoscopic and robotic abdominal surgery. By utilizing bio-absorbable anchors with a pre-attached suture, neoClose® is changing the standard of care in port site closure.  neoClose® is faster, safer, and provides less port site pain than the standard practice of closing port sites.

“With the acquisition of neoClose, Sharp Fluidics has expanded its product offerings beyond traditional open surgery, now providing a faster and safer surgical closure option for clinicians performing minimally invasive and robotic surgery,” said Mark Froimson, MD, MBA, Orthopedic Surgeon and Past President of the American Association of Hip and Knee Surgeons. “neoClose and Operative Armour reduce OR surgical times and improve OR staff safety, two of the most important initiatives that many leading hospitals have prioritized.”

OrthoSensor Receives 510(k) Alignment Clearance For VERASENSE™

OrthoSensor, Inc. announced today it has received a 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Alignment capabilities with VERASENSESensor-Assisted Technology, (VERASENSE), the only single-use intelligent sensor that measures tibial coronal alignment and quantifies soft-tissue balance when used with the Zimmer Biomet Persona Knee implant system (Persona).

VERASENSEis a sensor-assisted device used with leading knee implant systems during primary and revision Total Knee Arthroplasty (TKA). This technology transmits real-time data to a display unit in the operating room, which enables surgeons to make informed decisions about soft tissue balance and implant alignment. These are two major factors that contribute to the success of TKAs.

Dr. Martin Roche, Orthopedic Surgeon and Chief Medical Officer of OrthoSensor, Inc., said: “The ability to achieve optimal knee stability, implant congruency and alignment through the full range of motion is critical. The data that is provided from the single-use VERASENSE sensor will enable surgeons at hospitals and ambulatory surgery centers to make objective assessments intraoperatively of soft-tissue balance and knee alignment with the Persona implant system for the best possible patient outcomes1.”

“This FDA clearance of our Alignment technology for VERASENSE with Zimmer Biomet Persona is a great milestone for OrthoSensor.  OrthoSensor has always been committed to quantifying orthopedics through sensor-assisted technology and enable healthcare providers globally with evidenced-based treatments that improve clinical and economic outcomes for patients and healthcare stakeholders.  Our goals are not limited to knees; our innovations have expanded with the recent launch of our reverse shoulder device and will continue to expand to other orthopedic applications.  Our vision is to continue to lead the digital evolution of musculoskeletal care,” said Ivan Delevic, President and CEO of OrthoSensor, Inc.

1 Historically, roughly one in every five TKR patients (~20%) is dissatisfied with the results of their surgery. Common patient complaints include persistent pain, instability, stiffness, and loss in range of motion.1-3 Before VERASENSE; surgeons generally relied on their “best judgment” in determining what “felt” like a balanced knee or what “looked” well aligned.

The subjectivity of total knee replacement, coupled with improper soft tissue balance and implant position, may result in premature implant failure and the need for revision surgery in the future.6-10

In a prospective multi-center study, VERASENSE use was proven to reduce post-operative pain, accelerate patient activity levels, improve functional outcomes, and increase patient satisfaction scores with high statistical significance.2-5 In fact, 98 percent of patients whose knees were balanced using VERASENSE reported they were satisfied to very satisfied at three years post-op.2-5 These proven results point to improved joint balance being the key to higher TKR satisfaction.


References:

  1. Bourne RB, Chesworth B, Davis A, Mohamed N, Charron K. Comparing patient outcomes after THA and TKA: is there a difference? Clin Orthop Relat Res. 2010; 468: 542-546.
  2. Gustke K, Golladay G, Jerry G, Roche MW, Elson LC, Anderson CR. Increased Patient Satisfaction After Total Knee Replacement Using Sensor-Guided Technology. Bone Joint J. 2014 Oct;96-B(10):1333- 8.
  3. Gustke KA, Golladay GJ, Roche M, Elson L, Anderson C. Primary TKA patients with Quantifiably Balanced Soft-Tissue Achieve Significant Clinical Gains Sooner than Unbalanced Patients. Adv Orthop. 2014: 628695.
  4. Gustke KA, Golladay GJ, Roche MW, Elson LC, Anderson CR. A new method for defining balance: promising short-term clinical outcomes of sensor-guided TKA. J Arthroplasty 2014;29:955–960.
  5. 2-Year, 3-Year Clinical Outcomes, OrthoSensor Multicenter Evaluation. Pending Publication. Data on file at OrthoSensor, Inc.
  6. Parratte S, Pagnano MW. Instability after total knee arthroplasty. J Bone Joint Surg Am 2008; 90: 184–94.
  7. Bozic et al. The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res.2010; 468(1):45–51.
  8. Lombardi AV Jr1, Berend KR1, Adams JB1. Why knee replacements fail in 2013: patient, surgeon, or implant? Bone Joint J. 2014 Nov;96-B(11 Supple A):101-4.
  9. Schroer WC, Berend KR, Lombardi AV, et al. Why are total knees failing today? Etiology of total knee revision in 2010 and 2011. J Arthroplasty 2013;28(8 Suppl):116–119.
  10. Rodriguez-Merchan, EC. Instability Following Total Knee Arthroplasty. HSSJ. Oct 2011; 7(3): 273–278.

Xerox and Vortran Medical Partnering Allows for Mass Produce of Disposable Ventilators

Xerox Holdings Corporation and Vortran Medical Technology are teaming up to speed and scale production of Vortran’s GO2Vent ventilator and related Airway Pressure Monitor (APM-Plus) for hospitals and emergency response units fighting the battle against COVID-19.

The two companies expect to work together to quickly respond to the shortage of critical ventilation equipment necessary to support patients breathing. Assuming a stable supply of essential parts, the companies will be rapidly scaling up production from approximately 40,000 ventilators in April to between 150,000 and 200,000 ventilators a month by June. Together, Xerox and Vortran could produce as many as 1 million ventilators in the coming months.

While the GO2Vent is not a replacement for ventilators found in intensive care units (ICUs), it is widely used in emergency situations, inter-hospital transport and MRIs. Given the shortage of ICU-grade ventilators, medical professionals are utilizing tools like this and other technology to support patients who do not yet or no longer need an ICU-level breathing device, which can be freed up for another patient.

“Our smartest minds met (virtually) with Vortran’s smartest minds and figured out how to mass-produce this critical technology,” said John Visentin, vice chairman and chief executive officer, Xerox. “We want to help make sure doctors, nurses and paramedics on the frontlines have the resources they need to help the rising number of patients with COVID-19.”

Xerox plans to manufacture these FDA-approved ventilators and APM-Plus devices at its facility outside of Rochester, NY, where the company was founded and maintains a large presence. Vortran will continue to manufacture ventilators at its current facility in Sacramento, CA.

“The partnership with Xerox has one clear goal – to help save as many lives as possible. With Vortran’s proven technology and Xerox’s ability to hyper-scale manufacturing, we believe we can supply healthcare providers as many as 1 million ventilators in the coming months,” said Vortran Co-founder and CEO, Gordon A. Wong, M.D. “For all of us, this will be the most important thing we ever do.”

Vortran’s GO2Vent was designed for emergency use, natural disasters and disease outbreaks such as the COVID-19 pandemic. A gas-operated, disposable ventilator that can be set-up within minutes and discarded after use by a single patient, it provides support via a secure airway and can be operated on a compressor, oxygen or air with a minimum of 10 liters per minute flow rates.

The GO2Vent can provide continuous ventilatory support for up to 30 days and operates independently of Vortran’s APM-Plus. The APM-Plus is a battery-operated, portable device that connects to a GO2Vent and provides enhanced monitoring of patient status and key respiratory parameters. Given the need to confirm key supplies, the companies are actively assessing how quickly production can ramp for the APM-Plus devices.

In addition to scaling up production of the GO2Vent and APM-Plus, Xerox and Vortran expect to compile and analyze data and feedback from healthcare professionals on the frontlines of the battle against COVID-19 in order to design and mass-produce external, in-line modifications that can be added to the GO2Vent to expand the potential applications of this life-saving equipment.

Both Xerox and Vortran will distribute the products.

$1 Million COVID-19 Relief Fund is Launched by Inspire Brands: Fund to Support Childhood Hunger, Restaurant Industry Workers

The Inspire Brands Foundation, the charitable arm of Inspire Brands, is proud to announce the launch of a one million dollar COVID-19 relief fund, dedicated to supporting childhood hunger and restaurant industry relief efforts.

The initial disbursement from the fund is a $100,000 grant from the Arby’s Foundation, a division of the Inspire Brands Foundation, to support GENYOUth, a non-profit organization dedicated to creating healthier school communities. These funds will support GENYOUth’s newly established COVID-19 Emergency School Nutrition Fund and will provide up to 33 schools across the country grants of $3,000 each to purchase supplies for meal distribution and delivery.

“As a restaurant company, serving others is at the heart of who we are and how we operate,” said Stuart Brown, executive director of the Inspire Brands Foundation. “We’re hopeful that with community support, we can grow this fund beyond our initial investment, allowing us to serve more impacted youth and restaurant workers through the summer months and beyond.”

To help support / donate America’s youth and restaurant industry workers through a charitable donation.

Hope Biosciences Receives FDA Approval to Commence First Stem Cell Clinical Trial for Protection Against COVID-19

Hope Biosciences is a clinical stage biotechnology company developing cell-based therapeutics for acute and chronic disease. Today they announced that FDA has approved a Phase II clinical trial evaluating efficacy and safety of Hope Biosciences’ autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) to provide immune support against COVID-19.

MSCs are well-known for their immunomodulatory and regenerative potential. In a recent Phase I/II clinical trial for Rheumatoid Arthritis, results appeared to show that HB-adMSCs were safe and effective in attenuating systemic inflammation. In COVID-19 patients, inflammation is a driving force behind disease progression, and it is critical to regulate the immune system as early as possible.

“This study will utilize our proprietary core technology to deliver high quality, pure mesenchymal stem cells with standardized doses and multiple treatments. Our novel technology allows us to overcome the burdens of traditional cell therapy, such as inability to make enough cells to make a significant impact. We can produce, on-demand, over 1,000 highly concentrated HB-adMSC treatments from a single tablespoon of the patient’s own fat tissue. Most people who have been severely affected by COVID-19 had preexisting conditions. We are pretreating participants who are at higher risk of developing severe COVID-19, with the belief that we can prepare their immune systems, giving them their best chance to fight the virus,” said Donna Chang, President and CEO of Hope Biosciences.

This Phase II study is a single-arm, non-randomized study that is expected to enroll 75 participants that are either 50 years of age, have preexisting health conditions, or are at high-exposure risk. The study’s primary objective is to determine the efficacy of HB-adMSCs to prepare the immune system so that it is better able to fight the virus, should one become infected. We anticipate that this pretreatment will limit the progression and severity of COVID-19, ultimately keeping patients out of the hospital and off of mechanical ventilation. HB-adMSCs are administered via five intravenous infusions over a fourteen-week period and follow-up evaluations through 6 months. All participants will be monitored for changes in health status, including immune cell levels, inflammatory markers, and requirements for supplemental care or hospitalization.

This is the first of three New Drug Applications (INDs), related to COVID-19, that Hope Biosciences has filed with FDA. This initial protocol is specifically designed for patients who already have their own stem cells banked with Hope Biosciences. The next two protocols will utilize a donor cell source that will aim in protecting against COVID-19 for those at high risk (patients and frontline workers) and treating hospitalized patients.

“Our ultimate goal is to prevent anyone from needing mechanical ventilation. We believe that interceding early in the inflammatory process will give us the best possible outcome. Treating the disease is very important but if we have a chance to prevent the condition, we must explore all options. We appreciate the FDA’s willingness to take this groundbreaking approach at such a critical time for our nation,” said Donna Chang.

PAN Foundation Launches COVID-19 Treatment and Prevention Fund to Help At-Risk Medicare Beneficiaries Pay for Treatment, Groceries and Other Critical Services

PAN Foundation, is an independent charitable organization dedicated to helping underinsured patients access critical medical care. Today they announced that it will offer financial assistance to Americans with existing medical conditions who have COVID-19 or are quarantined because of the virus.

Through this comprehensive fund, PAN will provide a $300 grant to qualifying Medicare beneficiaries with cancer, chronic or rare diseases who have also been diagnosed with COVID-19 or directed to self-quarantine by their healthcare provider or a government agency. Grant recipients can use the funds for treatment co-pays, prescription and over-the-counter medications, medical supplies and other important expenses related to COVID-19 prevention and treatment, including transportation to medical appointments and groceries, meals and food delivery services.

“The COVID-19 pandemic is a stark reminder of the importance of our mission to ensure that every American can afford the healthcare they need. While we don’t know the full impact of this outbreak, we’re dedicated to doing everything we can to protect and support the most vulnerable members of our society,” said PAN President and CEO Daniel J. Klein. “As Medicare beneficiaries and people with serious health conditions learn to cope with this rapidly evolving situation, we’re committed to providing assistance to help those who need it most so they can focus on getting better and worry less about the cost of care.”

The results of a recent poll by the Commonwealth Foundation highlight the collective worry of Americans about their ability to afford medical treatment: 68 percent of adults said that the out-of-pocket costs they might have to pay would be very or somewhat important in their decision to get treatment if they had symptoms of the coronavirus.

The COVID-19 Treatment and Prevention Fund is currently open for applicants who have annual household incomes up to 400 percent of the federal poverty level. Eligible patients can learn more about the fund on our website or by calling PAN at 1-866-316-7263 from Monday through Friday, 9 a.m. to 7 p.m. ET.

Partnership Between Cummins and DuPont: To Use Filter Technology to Supply Critical Material for N95 Respirator Masks

As the COVID-19 pandemic spreads across the globe, Cummins Inc. (NYSE: CMI) and DuPont (NYSE: DD) is helping address the nation’s shortage of N95 respirator masks. Cummins’ NanoNet® and NanoForce® Media technology, which uses DuPont’s Hybrid Membrane Technology (HMT), can typically be found in air, fuel and lube filtration products used in heavy-duty diesel engines to prevent long-term engine wear, but also can be used in the N95 respirator masks worn by healthcare professionals to filter harmful airborne particles that can spread COVID-19.

The need for N95 masks has skyrocketed in recent weeks in response to the COVID-19 pandemic. Many of the world’s leading mask manufacturers are in need of the critical materials to assemble the mask and are struggling to meet demand.

“Cummins is re-evaluating our supply base and manufacturing capabilities to identify how we can support our healthcare professionals who rely on critical personal protective equipment to do their jobs,” said Amy Davis, Vice President of Cummins Filtration. “Our NanoNet® Media can fill a key supply void and help address the mask shortage facing the United States and other countries around the world.”

The first mask prototypes using Cummins’ donated media were assembled by the University of Minnesota teams in March as part of an initiative to provide masks to M Health Fairview and other Minneapolis-based healthcare systems. As the COVID-19 outbreak escalated, the University of Minnesota realized their supply of N95 masks to protect healthcare workers would potentially run out in a matter of weeks. To address this challenge, a team of designers, engineers, chemists, surgeons, anesthesiologist and apparel and clothing experts from the University of Minnesota’s Institute for Engineering in Medicine; Medical School; College of Design; College of Science and Engineering; and Center for Filtration Research Consortium (CFR) came together to address this projected shortage of critical personal protective equipment.

“The first thing we recognized from our experts in the Center for Filtration Research, who work directly with Cummins, is that not all filtration materials are created equal and that the Cummins material is an excellent alternative,” said Jakub Tolar, Campus Health Officer, and Medical School Dean at the University of Minnesota. “We are tremendously grateful for the generous donation from Cummins of their filtration materials toward our mask effort. Since the arrival of the filtration media, we have been able to make rapid progress, and we now believe we have several viable mask options, including both a disposable and reusable option. These designs show real promise in keeping our healthcare workers safe should standard medical supplies of N95 masks no longer be available,” continued Tolar.

The project also aims to provide open-source instructions that other healthcare systems and groups can use to create their own respirator masks.

While DuPont’s innovative and unique Hybrid Membrane Technology (HMT) is typically integrated with Cummins’ synthetic fibers to protect sensitive engine components, it has multiple other applications that can include filtration media used in N95 respirator masks.

DuPont’s Hybrid Membrane Technology goes beyond the limits of traditional semi-porous or nonwoven membranes for air and liquid filtration. Made using a proprietary spinning process, the hybrid technology materials are comprised of continuous sub-micron fibers. The end result is a “membrane-like” sheet structure that balances breathability and high filtration efficiency of particulates.

“We are proud to make our advanced technology available to help protect more caregivers on the front lines of this global health crisis,” said HP Nanda, Global Vice President & General Manager, DuPont Water Solutions. “We thank our partner Cummins for transitioning the use of its production line to help address the global shortage of N95 mask materials, and we thank the experts at the University of Minnesota for their leadership in testing and designing several mask options for the benefit of many healthcare systems. By working together—and innovating new applications of existing technologies and materials—we hope to slow the spread of this terrible virus.”

The N95 designation means the respirator can block at least 95 percent of particles from entering the wearer’s nose and mouth. When Cummins’ NanoNet® Media was tested using an industry-standard testing method, it exceeded the performance requirements for N95 designation. Cummins’ manufacturing facilities have since provided media samples to mask manufacturers across the globe to test its effectiveness.

While products featuring Cummins’ media will need to be vetted and approved by the National Institute for Occupational Safety and Health (NIOSH), the company is preparing to do its part to help relieve the burden facing the healthcare industry. “We’re working as quickly as possible with healthcare regulators and other partners to help certify products with our materials, and prepare our manufacturing facilities to meet demand,” said Davis.

Mask manufacturers interested in learning more about Cummins’ media technology can visit cumminsfiltration.com/respiratormedia.

Cummins’ Filtration business designs, manufactures and sells air, fuel, hydraulic and lube filtration, as well as chemical technology products for diesel and gas-powered equipment around the world.